Key Highlights
•
In a large real-world study of multiple sclerosis patients, the drug natalizumab was more effective at reducing relapse rates and improving disability than anti-CD20 therapies like ocrelizumab and rituximab. This finding helps doctors choose the most effective treatment for individual patients, as natalizumab also caused fewer side effects.
Source →
•
A new study on Alzheimer’s disease found that the antibody drug lecanemab binds to the same type of amyloid-beta protein clumps in the brain as other similar antibodies. This suggests that the lower risk of brain swelling seen with lecanemab is not due to it targeting a different form of the protein, pointing to other factors at play.
Source →
•
Researchers found that male and female mice show different patterns of brain activity when exposed to short-term and long-term stress. This finding highlights the importance of considering sex-specific biological responses in developing future treatments for stress-related neurological conditions.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
